Dr. Reddy’s Announces the Launch of Donepezil Hydrochloride Tablets, 23 mg
Dr. Reddy’s Laboratories (NYSE: RDY) announced yesterday that it has
launched Donepezil Hydrochloride Tablets, 23 mg, a therapeutic
equivalent generic version of ARICEPT®, 23 mg in the U.S.
market on July 26, 2013, following the approval by the United States
Food & Drug Administration (USFDA) of Dr. Reddy’s ANDA for Donepezil
Hydrochloride Tablets, 23 mg.
The ARICEPT®, 23 mg brand had U.S. sales of approximately
$92.6 Million MAT for the most recent twelve months ending in May 2013
according to IMS Health*.
Dr. Reddy’s Donepezil Hydrochloride Tablets, 23 mg is available in
bottle count sizes of 30 and 90.
Disclaimer
This press release includes forward-looking statements, as defined in
the U.S. Private Securities Litigation Reform Act of 1995. We have based
these forward-looking statements on our current expectations and
projections about future events. Such statements involve known and
unknown risks, uncertainties and other factors that may cause actual
results to differ materially. Such factors include, but are not limited
to, changes in local and global economic conditions, our ability to
successfully implement our strategy, the market acceptance of and demand
for our products, our growth and expansion, technological change and our
exposure to market risks. By their nature, these expectations and
projections are only estimates and could be materially different from
actual results in the future.
About Dr. Reddy’s
Dr. Reddy’s Laboratories Ltd. (NYSE: RDY) is an integrated global
pharmaceutical company, committed to providing affordable and innovative
medicines for healthier lives. Through its three businesses -
Pharmaceutical Services and Active Ingredients, Global Generics and
Proprietary Products – Dr. Reddy’s offers a portfolio of products and
services including APIs, custom pharmaceutical services, generics,
biosimilars and differentiated formulations. Major therapeutic focus is
on gastro-intestinal, cardiovascular, diabetology, oncology, pain
management and anti-infective. Major markets include India, USA,
Russia-CIS and Europe apart from other select geographies within
Emerging Markets.
For more information, log on to: www.drreddys.com
ARICEPT® is a trademark used by Eisai Inc. under license from
Eisai R&D Management Co., Ltd.
*IMS National Sales
Perspectives: Retail and Non-Retail MAT May 2013
Copyright Business Wire 2013